Endoscopic gastric remodeling achieved complete reversal of metabolic dysfunction-associated steatohepatitis (MASH) in 46% of patients after one minimally invasive procedure. The technique reduced median weight by 16.5% over 12 months, with 73% achieving clinically meaningful weight loss and 54% showing improved liver fibrosis. This represents a significant advance in treating what has become the leading cause of liver transplants in younger adults. Current first-line treatments—lifestyle changes and GLP-1 receptor agonists—face adoption barriers due to poor adherence and cost respectively. EGR offers a middle ground between ineffective behavioral interventions and invasive bariatric surgery. The procedure works by reducing stomach capacity through endoscopic tissue folding, requiring no external incisions. However, the small sample size of 20 patients, with only 13 completing follow-up, limits confidence in these results. The 35% dropout rate also raises questions about real-world effectiveness. While promising, larger randomized controlled trials are needed before EGR can be considered standard care. The finding that a single intervention can reverse advanced liver disease represents an incremental but potentially important step forward in metabolic medicine.